Cargando…
iNKT: A new avenue for CAR-based cancer immunotherapy
Chimeric antigen receptor (CAR) T cell is a T lymphocyte-based immunotherapy, which achieves great successes in treating blood malignancies and provides new hope to cue advanced cancer patients. Invariant natural killer T (iNKT) cells are a kind of special T lymphocytes characterized by expressing i...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784340/ https://www.ncbi.nlm.nih.gov/pubmed/35063813 http://dx.doi.org/10.1016/j.tranon.2022.101342 |